Oppenheimer lowered the firm’s price target on Vor Bio to $15 from $17 on revised cash guidance, while keeping an Outperform rating on the shares following quarterly results. The firm notes recruitment into both of the company’s ongoing trials was described as “robust.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VOR:
- Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
- VOR Upcoming Earnings Report: What to Expect?
- Vor Bio treatment of acute myeloid leukemia granted FDA orphan designation
- Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Vor Bio to Participate in Upcoming Investor Conferences
